Background: Historically, periodontal regeneration has focused predominantly on bone substitutes and/or barrier membrane application to provide for defect fill and/or selected cell repopulation of the lesion. More recently, a number of technologies have evolved that can be viewed as emerging therapeutic approaches for periodontal regeneration, and these technologies were considered in the review paper and by the consensus group. The goal of this consensus report on emerging regenerative approaches for periodontal hard and soft tissue reconstruction was to develop a consensus document based on the accompanying review paper and on additional materials submitted before and at the consensus group session.
M embers of Emerging Regenerative Approaches for Periodontal Reconstruction consensus group met and began with individual introductions and provision of appropriate disclosures. The authors of the written review provided a summary of the construction and contents of the review paper. 1 Each member of this consensus group provided comments on the review.
As an overview, one of the issues arising was the question of defining what constitutes an emerging technology. The group considered two broad categories: 1) products and components of products approved by the Food and Drug Administration (FDA) and 2) nonapproved therapeutic modalities. For example, components of FDA-approved products are being examined for periodontal regeneration and thus were considered an emerging therapeutic approach. In addition, currently available therapeutics that have limited data supporting their use in periodontal regeneration were also considered an emerging technology.
We discussed the contents of the review paper and made suggestions for additions. The consensus group agreed with the contents of the review paper and the scope of products and technologies that were covered in the paper with the additions and comments noted below.
Most of the emerging approaches discussed in the review paper were focused on the concepts of tissue engineering and also included other approaches. The topics discussed included the following: 1) protein and peptide therapy; 2) cell-based therapy; 3) genetic therapy; 4) scaffolds; 5) bone anabolics; and 6) lasers. FDA-approved products evaluated included the following: 1) enamel matrix derivative; 2) recombinant human platelet-derived growth factor; and 3) anorganic bone matrix. Non-approved therapeutic modalities included the following: 1) recombinant human fibroblast growth factor-2; 2) recombinant human growth differentiation factor-5; 3) bone morphogenetic proteins (BMP-2, BMP-7, BMP-6, and BMP-12); 4) parathyroid hormone/ teriparatide; 5) brain-derived neurotrophic factor; and 6) sclerostin antibodies. Cell-based therapies included the following: 1) mesenchymal stem cells; 2) bone marrow stromal cells; 3) periodontal ligament cells; 4) embryonic stem cells; and 5) induced pluripotent stem cells. Gene therapies included viral and non-viral vectors. Scaffolds are also promising for delivery of growth factors and gene therapy and may be composed of either natural or synthetic polymeric materials. Finally, various types of lasers were discussed.
In addition to the approaches highlighted in the review, the consensus group recognized that many of the therapeutics in current use are based on fundamental knowledge and understanding of the development of the periodontium. Furthermore, the host inflammatory response should also be considered, as well as such interactions between the host genome, epigenetics, and the microbiome. Areas of future interest might include inflammatory regulators such as resolvins and interleukin-17 antibodies, as well as phosphate/pyrophosphate local regulation.
Implications of Review to Patient-Related Clinical Outcomes
The review did not identify any reports addressing patient-reported outcomes. However, the review did reveal clinical parameter-based outcomes of several individualized approaches over various time periods, with the longest follow-up being 3 years in one report of 83 patients. Although there are multiple papers focused on various emerging technologies, there are no studies that allow for direct comparison of clinical outcomes.
When dealing with emerging technologies, there can be both positive and negative issues of clinician adoption and patient acceptance of treatment.
Barriers to adopting this technology include limited evidence supporting efficacy and indications for use. With emerging technologies, safety issues include unknown long-term effects along with known risk for rare but serious side effects, such as sarcoma. This is, in part, attributable to evaluation of such emerging technologies in populations defined by selected inclusion/exclusion criteria, further limiting outcome assessments.
With any emerging technology, the cost-to-benefit ratio for clinicians and patients must be determined. For the clinician, peer and market pressures, surgical time, technical complexity, healing times, predictability, liability, and cost must be considered.
For patients, experience of pain and morbidity, adverse events, both short and long term, cost, time, material (ethical and religious concerns), esthetic perceptions, and satisfaction with treatment outcomes should be considered. the periodontium as a functional organ system. The review made a number of recommendations, and the consensus group highlighted that future studies should do the following: 1) develop a non-invasive assessment of clinical periodontal regeneration; 2) evaluate the efficacy and safety of combining emerging and/or current therapies; 3) validate existing and/or emerging therapies being used ''off label''; 4) explore therapies developed for other purposes for their application to periodontal regeneration; 5) define the individual's genetic and epigenetic profile so that it can be used to personalize the choice of therapy; 6) assess the effect of individual disease pathogenesis, etiology, and healing potential on therapeutic treatment selection; 7) optimize the understanding of risk factors to aid in the selection of appropriate therapy and the achievement of enhanced outcomes to restore the structure and function of the periodontium; 8) define molecular and cellular mechanisms of the emerging therapy using in vitro and in vivo models; 9) identify developmental pathways of the periodontium for potential application in regenerative therapy; 10) focus on developing minimally invasive technologies to minimize pain and morbidity without compromising outcomes; 11) define what constitutes clinical success; and 12) characterize the effect of the selected therapy on the patient's quality of life.
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